Skip to main content
ImmuneCited

Pelargonium sidoides 관련 Acute Bronchitis

A

Meta-analyses demonstrate Pelargonium sidoides (EPs 7630) may significantly reduce bronchitis symptom severity and working inability. Approved as a medicine for respiratory infections in multiple countries. RCT showed working inability decreased to 16% vs 43% in placebo group after 7 days.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dpelargonium\u002Dsidoides\u0026condition\u003Dacute\u002Dbronchitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

결론

Meta-analyses demonstrate Pelargonium sidoides (EPs 7630) may significantly reduce bronchitis symptom severity and working inability. Approved as a medicine for respiratory infections in multiple countries. RCT showed working inability decreased to 16% vs 43% in placebo group after 7 days.

Key Study Findings

Other
Research Landscape and Emerging Trends in Herbal Medicine for Pediatric Respiratory Tract Infections: A CiteSpace-Based …
Dose: None vs: None Outcome: research landscape of herbal medicine for pediatric RTIs 효과: None None

대상 집단: pediatric patients with respiratory tract infections

Systematic Review
Pelargonium sidoides - from ethnopharmacology to evidence-based medicine: a systematic review.
Dose: None vs: None Outcome: clinical efficacy of Pelargonium sidoides for respiratory tract … 효과: None None

대상 집단: patients with acute bronchitis, rhinosinusitis, and tonsillopharyngitis

Randomized Controlled Trial n=240 1 weeks Double-blind
Efficacy and Safety of YJP-40 in Patients with Acute Bronchitis: A Randomized, Double-Blind, Parallel Group …
Dose: None vs: Umckamin syrup (P. sidoides extract alone) Outcome: Change in bronchitis severity score (BSS) at day … 효과: BSS change: -4.31 vs -4.36 non-inferiority demonstrated

대상 집단: Patients with acute bronchitis from 7 hospitals

Randomized Controlled Trial 1 weeks Double-blind
Efficacy and safety of mixture of ivy leaf extract and coptidis rhizome in the treatment …
Dose: Ivy leaf extract + Coptidis rhizome vs: Pelargonium sidoides extract Outcome: Bronchitis severity score (BSS) 효과: None None

대상 집단: Adults with acute bronchitis

Review
Chronobiological Efficacy of Combined Therapy of Pelargonium Sidoides and Melatonin in Acute and Persistent Cases …
Dose: None vs: None Outcome: inflammation markers 효과: None None

대상 집단: Covid-19

Randomized Controlled Trial n=591 1.0 weeks Open-label
Safety of Pelargonium extract EPs 7630 in young children with acute bronchitis.
Dose: 7.2% vs: None Outcome: None 효과: None None

대상 집단: Ab received eps 7630 syrup or solution for 7 days

Key Statistics

8

연구

2000

참여자

Positive

A

등급

Referenced Papers

The Cochrane database … 2013 125 인용
Phytomedicine : international … 2008 100 인용
The Cochrane database … 2008 71 인용
Wiener medizinische Wochenschrift … 2007 23 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:
30 drops (1.5 mL) liquid extract 3x/day or 20 mg EPs 7630 tablets 3x/day
duration:
7-14 days

상한량: No established UL

연구에서 사용된 용량

용량 기간 효과 N
None -- Positive --
None -- Positive --
None 1 weeks Neutral 240
Ivy leaf extract + Coptidis rhizome 1 weeks Positive --
None -- Mixed --
7.2% 1.0 weeks Positive 591
83.6% 10.4 weeks Mixed 505
None -- Positive 2195

권장 복용 시간: At onset of respiratory symptoms; 3x daily for up to 14 days

Safety & Side Effects

보고된 부작용

  • Gastrointestinal discomfort (rare)
  • Allergic skin reactions (rare)
  • Nosebleeds (rare)
  • Hepatotoxicity (very rare, case reports)

알려진 상호작용

  • Anticoagulants (theoretical increased bleeding risk due to coumarin content)
  • Immunosuppressant medications (may modulate immune function)

일일 최대 섭취 허용량: No established UL

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does Pelargonium sidoides help with Acute Bronchitis?
Based on 8 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Pelargonium sidoides may support Acute Bronchitis management. Our evidence grade is A (Strong Evidence).
How much Pelargonium sidoides should I take for Acute Bronchitis?
Studies have used various dosages. A commonly studied range is 30 drops (1.5 mL) liquid extract 3x/day or 20 mg EPs 7630 tablets 3x/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Pelargonium sidoides?
Reported side effects may include Gastrointestinal discomfort (rare), Allergic skin reactions (rare), Nosebleeds (rare), Hepatotoxicity (very rare, case reports). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Pelargonium sidoides and Acute Bronchitis?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Related Evidence

관련 다른 성분: Acute Bronchitis

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.